The biotech company's stock advanced following the announcement that enrollment in a diabetes clinical trial has concluded.
Biomea Fusion’s shares climbed after the company reported that enrollment in a diabetes clinical trial has been completed. The development marks a step forward in the firm’s clinical research program.
Further details about the trial’s design or timeline were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
